Searched for
PHARMACEUTICAL STOCKS
Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...- Forget short-term pressure; in the long term, the right business is what pays: 5 mid-cap stocks with an upside potential of up to 36%We have said this before, and we say it again: No one can predict when the market will bottom out. You can see the bottom only in hindsight...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 croreMankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, s...
- India’s ₹1 lakh crore club stocks hit hard by FII exit. Have bluechips lost their growth engines?India's largest corporations are experiencing a notable drop in foreign institutional investor stakes, raising concerns about their growth ...
- Indian markets rebound, but rising oil prices keep investors cautiousOn Monday, Indian equity markets staged a comeback following four days of losses, with both the BSE Sensex and NSE Nifty seeing notable gai...
- US stocks face crucial test as AI earnings, Fed meeting loomUS stocks face a crucial week as earnings from Alphabet, Microsoft and Amazon coincide with the Federal Reserve’s policy decision. Investor...
- Two Trades for Today: A digital tech solutions company for a 5.4% rise, a top pharma stock for an almost 7% gainOur technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginallyDr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America ...
- GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan saysThe China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan esti...
- Jio’s mega public issue puts India’s AI companies in the spotlight; see who are the potential IPO candidatesThe interest in India’s AI firms comes at a time when such companies are attracting increasing private investment and some are beginning to...
- How Vivek Ramaswamy built his billion-dollar fortune through biotech, stock sales and investments — and what he still ownsVivek Ramaswamy's Net Worth: Vivek Ramaswamy’s estimated $2.2 billion to $2.3 billion fortune was built through biotech deals, stock sales ...
- Two Trades for Today: A top pharma company for a 6.3% upmove, a large-cap hospitality stock for a gain of almost 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Every bad cycle ends the same way; problems find their own solutions: 5 large-cap stocks with upside potential of up to 27%What should you focus on when headwinds blow? Not the share price, and not the morning's news. It should be the business and the quality of...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsThe last few weeks have made one thing clear. Oil prices, US bond yields, corporate earnings, and the state of the world – all point the sa...
- US targets $500 billion India trade in 3 years, up from record $240 billion, Sergio Gor saysThe United States plans to increase bilateral trade with India to over USD 500 billion in three years. This trade target comes after reachi...
- 5 stocks with consistent score improvement and upside potential of up to 29 % in 1 year, according to analystsLook at how the market treated the stock of a large FMCG stock – one the best wealth creators of the past – just because it mentioned the r...
- Donald Trump raised stakes in drug companies gaining from medicare exemptions, say DemocratsInvestments in pharmaceutical companies on behalf of Donald Trump saw a significant increase after returning to the White House. His portfo...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsThe next few weeks are critical, and one should not be in a hurry to make market-related decisions. Better to be cautious – to wait and wat...
- Long-term investing is about looking beyond narratives, including AI: 5 large-caps with an upside potential of up to 24%As we see a recovery in the market, it is good to be cognizant of the fact that more than the narratives on the street, it is the earnings ...
Load More
